



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61M 25/10, 29/02, A61B 17/12	A1	(11) International Publication Number: WO 96/27406 (43) International Publication Date: 12 September 1996 (12.09.96)
--	----	---

(21) International Application Number: PCT/IB96/00143

(22) International Filing Date: 26 February 1996 (26.02.96)

(30) Priority Data:
08/399,789 7 March 1995 (07.03.95) US(71) Applicant: AMERICAN MEDICAL SYSTEMS, INC.
[US/US]; 11001 Bren Road East, Minnetonka, MN 55343 (US).


(72) Inventors: BURTON, John, Hanley; 15460 Wing Lake Drive, Minnetonka, MN 55345 (US). STAEBLE, Bradford, George; 17220 Creek Ridge Pass, Minnetonka, MN 55345 (US).

(74) Agents: SPIEGEL, Allen, J. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).

(81) Designated States: AU, CA, DE (Utility model), JP, MX, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.

(54) Title: SLOWLY DILATING DEVICE FOR THE URETHRA



(57) Abstract

A device for dilating at least an obstructed portion (12) of the urethra (10), includes a urinary catheter (22) having a proximal portion and a distal portion; a dilation balloon (34) capable of expanding radially outwardly disposed between the proximal and distal portion of the catheter (22); and a pressure source (32) capable of sequentially contracting under pressure. The pressure source (32) and dilation balloon (34) are in fluid communication through a conduit (44 or 46) which enables fluid to flow from the pressure source (32) to the dilation balloon (34) at a predetermined gradual rate when the pressure source (32) is contracting, whereby the balloon (34) expands gradually radially outwardly to effect the slow dilation of the urethra (10 and 12). A method for dilating the obstructed portion (12) of the urethra (10) and for treating prostatic hyperplasia is also provided.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

-1-

5 SLOWLY DILATING DEVICE FOR THE URETHRA Technical Field

 This invention relates generally to dilation devices for the urethra and to the treatment of hypertrophy of the prostate gland. More specifically it relates to novel devices for slowly dilating obstructed portions of the urethra, and to concomitant
10 methods for slowly dilating an obstructed portion of the urethra and for treating benign prostate hyperplasia (BPH).

 Benign prostate hyperplasia is a condition which affects well over 50% of the male population over 50 years of age. The treatment of BPH is a matter of great medical and commercial importance. On a worldwide basis, upwards of four billion
15 dollars are spent annually in the treatment of this condition.

Background Art

 There are many devices, techniques and methods which are presently being employed for treating BPH. Surgical treatment of hypertrophy of the prostate has been a routine procedure for many years. One method of such surgical treatment is open
20 prostatectomy wherein the gland is totally or partially removed. Another method of surgical treatment is transurethral resection of the prostate (TURP). However while surgical treatment can be effective it remains an extremely invasive procedure which is debilitating, painful and often traumatic to the patient. Various complications including impotence, incontinence, bleeding, infection and other undesirable problems attendant
25 with such surgery can result. The need for less invasive procedures is therefore of considerable importance.

 Among the less invasive procedures now being employed is that of using catheters which are placed in the external opening of the urethra and into at least the obstructed portions of the urethra which allow the passage of urine from the bladder
30 by way of the catheter lumen. These urinary catheters typically employ a positioning or retention balloon at the distal tip which, at the bladder neck, when inflated, prevents the expulsion of the catheter from the body. Illustrative of such positioning balloon catheters are those known in the art as Foley catheters.

 It has also been proposed to utilize inflation balloons in addition to positioning
35 balloons for the purpose of dilating obstructed portions of the urethra. Illustrative of such type balloons are those described in U.S.P. 4,932,958 to Reddy.

-2-

It has also been proposed to utilize heat in combination with such catheters for treating the enlarged portion of the prostate, such heat being provided by a variety of means including the use of microwave or laser energy.

Again, while these methods and devices are useful, the search for even less
5 invasive devices and procedures continues. The need for devices and procedures which will result in less pain and discomfort to the patient is of substantial interest, as is the desirability of providing means and devices which will provide for longer term patency of a dilated urethra, i.e. to effect a longer lasting result on relieving the obstruction in the urethra caused by the hypertrophied prostate gland. The latter, due
10 to its resilient fibrous structure and large bulk tends to rebound after treatment of the obstructed urethra is completed, resulting in renewed obstruction.

It would be very desirable, therefore, to provide devices and methods for treating BPH which would be much less invasive and painful, and which would result in dilated urethras of longer patency.

15 Illustrative of a somewhat less invasive approach is found in the U.S.P. 4,762,128 to Rosenbluth. This patent discloses an expansion catheter having a rapidly expandable tubular stent associated therewith, which is adapted for transurethral insertion via the external opening of the urethra and for placement within an obstructed region of the urethral lumen caused by a hypertrophied prostate gland. Removal of the
20 expansion catheter leaving in place an expanded tubular stent may result in long term patency of the urethral lumen. Though the stent is also adapted to be removable from the urethra, the intent of the device is to establish a long-term implant.

 In U.S. Patent 5,163,952 to Froix there is disclosed an expandable stent for use in a lumen defined by a wall of a vessel, which illustratively is defined as an arterial
25 vessel in the heart. The polymeric stent has a built-in elastic predetermined diameter and a memory of a diameter greater than the predetermined diameter which is assumed upon activation of a thermal activation point by the adsorption of heat by the plastic, adsorption of liquid by the plastic, or a change in the pH of the liquid surrounding the plastic.

30 In U.S. Patent 5,084,060 there is provided an apparatus for applying fluidic pressure to the inside of a body vessel during selected intervals to incrementally enlarge the lumen of the vessel.

-3-

In U.S. Patent 4,660,560 to Klein there is disclosed a method for treating obstructive prostatism which comprises measuring the distance between the bladder neck and the veru montanum, inserting a dilating catheter into the urethra, and positioning the same, such as through the use of a positioning balloon which can be
5 located in the bladder neck.

Published PCT Patent Application WO 95/03848 discloses a method and device for slowly dilating the urethra utilizing a hollow member permitting urination therethrough from the bladder, and hydrophillic means associated therewith which are capable of absorbing water and slowly swelling, thereby dilating the urethra.

10 Brief Disclosure of the Invention

In its broadest context, the present invention relates to a device for slowly dilating an obstructed portion of the urethra, which comprises a urinary catheter, for insertion in the prostatic urethra, having a proximal portion and a distal portion. Disposed on the catheter between the proximal and distal portion is dilation means
15 having a length of at least that of the obstructed portion of the urethra. Also provided is pressure responsive means which is capable of sequentially contracting under pressure, the pressure responsive means and the dilation means being in fluid communication with each other. When the pressure responsive means contracts under pressure, fluid flows therefrom into the dilation means at a predetermined rate to cause
20 the dilation means to expand gradually (and controllably) in a radially outwardly direction, and with sufficient impacting force to cause the obstructed portion of the urethra to dilate to a desired diameter and configuration.

Also in its broadest context, the present invention provides a method for slowly dilating an obstructed portion of a urethra by the sequential transfer of fluid from
25 pressure responsive means, which is capable of expanding and contracting, into dilation means which are thereby radially expanded, the expanded dilation means thereby impacting upon the obstructed portion of the urethra with sufficient, and preferably constant, force to cause the latter to gradually dilate to a desired diameter and configuration.

30 The present invention also provides a method for treating benign prostatic hyperplasia which comprises the aforesaid method of dilating an obstructed portion of the urethra thereby relieving the obstruction caused by the hypertrophy of the prostate gland.

In one embodiment of this invention, a single inflation/deflation lumen is provided to effect initially the full inflation of the pressure responsive means, and (less than complete) inflation of the dilation means. In the latter case, the extent of dilation is thereby not adequate, or only partially adequate, to dilate the urethra in the manner
5 desired. In this embodiment the subsequent contraction (and at least partial deflation) of the pressure responsive means results in the necessary full inflation of the dilation means thereby resulting in the dilation of the urethra.

In a preferred embodiment of this invention, the pressure responsive means is disposed at or near the distal portion of the catheter and is capable of initially being
10 inflated to a maximum extent due to the onset of fluid, from a single inflation lumen or conduit. This lumen can also act to transfer fluid to the dilation means upon contraction of the pressure responsive means. However, it is also preferred that the flow of liquid from the pressure responsive means, when it is in a contracting mode, be effected through a separately disposed conduit or lumen, as hereinafter described. In
15 this embodiment, the flow of fluid proceeds at a controlled rate, typically through fluid resistor means, which can be of the kind known in the art.

The slow or gradual dilation of the urethra has the significant advantage of alleviating or lessening the discomfort felt by the patient which is the concomitant effect when rapid dilation of the urethra occurs, i.e. on the order of 10 minutes or less, as is
20 the case with the usual dilation currently effected by most prior art devices. In the context of this invention, an expansion rate of between about 5 French and about 20 French over a 24 hour period is desirable to effect the dilation of at least the obstructed portion of the urethra to a maximum or desired diameter and configuration.

In accordance with this invention, the dilation means, disposed on the catheter
25 is usually in the form of a dilation balloon having an outer surface capable of expanding radially outwardly for a period of at least about 30 minutes. The length of the dilation balloon on the catheter should correspond to the length of at least that of the obstructed portion of the urethra. The inflation balloon can be elastic without a defined limit of intrinsic expansion or can also have a defined shape and an intrinsic limit to
30 expansion.

The pressure responsive means can optionally be in the form of an expandable and contractible balloon which can also act as a positioning balloon when located in the area of the bladder neck of the body. However, a separate positioning balloon can

-5-

also be disposed as part of the device of this invention as, for example, in the area of the bulbous urethra. However, other suitable means can be employed to fix or position the device of this invention.

Another aspect of this invention is the fact that it can be adapted to remain in the urethra for extended periods of time before removal. Such an extended presence can be on the order of at least about 5 days to about 30 days, the latter being a desirable upper limit because of clinical efficacy and patient comfort. As a consequence of the long presence of the expanded device in the urethra, the dilated urethral configuration will tend to remain in such configuration for an extended period of time, even after the device is removed. Up to 12-24 months or more is likely before obstruction of the prostatic urethra will occur again. This is a highly desirable result of this aspect of the invention. As stated above, in the prior means employed for rapidly dilating obstructed portions of the urethra, deformation of the urethral wall will often have a relatively short effect on relieving the obstruction of the prostatic urethra because the latter is caused by the continued pressure exerted by the hypertrophied prostate gland, due to the resilient viscoelastic nature of its tissue, and because of continued hypertrophy.

While the device of this invention can be in the form of a unitary catheter, it is also contemplated that the device can comprise a stent having the aforesaid dilation means and pressure responsive means thereon, which can remain in the dilated urethra for the desired time, and a removable section for inserting the stent, which can include a filling tube for effecting the initial flow of fluid into the stent. Any suitable attachable means can be provided for removing a unitary catheter after deflation of both the dilation means and the pressure responsive means. If the catheter comprises a stent and a removable section, the latter is by its nature removable by the simple act of withdrawing the section after it is detached from the stent. The means for removing the stent from the dilated urethra can be accomplished by any means known in the art, such as the use of clamps or pull strings.

Further objects, features and advantages of the present invention will become apparent from the detailed description of the drawings.

Brief Description of the Drawings

Fig. 1 is a simplified sectional view of the relevant anatomy of a male body, showing an obstructed urethra, an enlarged prostate gland, a bladder, and a schematic

-6-

unexpanded dilation device of the subject invention, as hereinafter described, which is positioned just before insertion into the obstructed portion of the prostatic urethra.

Fig. 2 is a sectional view of a portion of Fig. 1 depicting a portion of the dilation device, in a non-expanded state, implanted within the obstructed portion of the urethra.

5 Pressure responsive means is shown distally disposed inside the bladder.

Fig. 3 is a sectional view of the device shown in Fig. 2, in an expanded state, and indicating the concomitant dilation of the prostatic urethra, wherein the pressure responsive means, though partially deflated, is acting as a positioning balloon.

Fig. 4 is a schematic view of a dilation device of this invention, wherein the
10 pressure responsive means and dilation balloon are in fluid communication through a single lumen, the device further comprising a stent portion and a detachable inserter.

Fig. 5 is a schematic view of a dilation device of this invention wherein the pressure responsive means also serves as a positioning balloon, and a separate lumen provides further fluid communication between the dilation balloon and the pressure
15 responsive/positioning balloon.

Detailed Disclosure of the Invention

In the drawings like reference numerals are utilized for like parts throughout the several views. In Fig. 1 there is illustrated, in simplified form, a urethra 10 having an obstructed portion 12 about which is depicted an enlarged hypertrophied prostate
20 gland 14, which inferentially is pressing inwardly on the obstructed portion 12. Also shown is a bladder 16 having a neck 18 depending therefrom, and at the other end of the urethra is a penis 20. A dilation device 22 according to the subject invention, which will be hereinafter described, is shown in position to be inserted into the urethra 10, the device 22 comprising portion 24 having a length at least equal to that of the obstructed
25 portion 12.

In Fig. 2 there is shown a simplified sectional view of the portion 24 when placed in the obstructed portion of the urethra. The portion 24 is depicted in an unexpanded mode. Extending through the portion 24 is a draining lumen 28 having a bladder drainage port 30 in the distal portion of the device which communicates with the
30 drainage lumen, for permitting the flow of urine therethrough, i.e., from the bladder through the urethra and out of the penis. Protruding portion 26 can be attached to suitable means for insertion. The lumen 28 acts as a conduit having a diameter sufficient to permit urine to flow therethrough. A pressure responsive inflatable source

-7-

32 is shown disposed in the distal portion of the portion 24 which, when secured in the body, would usually be in the area of the bladder neck. Inflatable means 34, which is preferably in the form of a dilation balloon, is disposed along the outer surface of the portion 24 and has a length at least equal to that of the obstructed portion of the urethra.

The portion 24 of the device of the subject invention, wherein the inflatable means is in its unexpanded state, should be of a minimum diameter, including the pressure responsive means and dilation balloon, which would allow the device 22 to be inserted into the penis and then into the obstructed portion of the urethra with a minimum of discomfort. A suitable diameter in this regard should be about 20 to about 26 French. (1 French = 1/3 mm). The dilation balloon should be a material capable of expanding outwardly and radically so as to impact upon the obstructed urethra, in order to expand and dilate the obstructed portion 12 of the urethra 10 to a predetermined diameter and (dilated) configuration.

In Fig. 3, the dilation balloon 34 of the dilation device of this invention is shown in an expanded, inflated state with outer surface 36 impacting on the obstructed portion of the urethra. The portion 12 of the urethra, formerly obstructed by the hyperplasia of the prostate gland, is now shown in a dilated configuration. The pressure responsive means or pressure source 32 is initially completely inflated but in the final operable mode of this embodiment wherein the urethra is inflated, the pressure responsive means 32 is only partially inflated; however, it remains sufficiently inflated so that, in this embodiment, it also acts as a positioning balloon, located at the bladder neck.

In Fig. 4 there is shown a schematic cross-sectional view of another typical device of this invention. As depicted therein, a pressure source 32 is disposed in the distal portion of the device, on the portion 24, which is in the form of a stent, and a dilation envelope 34, which is preferably a balloon such as is normally used in this art, is disposed proximal to but not abutting with the pressure source. Downstream from the dilation balloon, but in this embodiment still a part of the stent, is a location or positioning balloon 38. In this embodiment, the pressure source 32 is adapted to be disposed in the bladder while the positioning balloon 38 is adapted to be disposed in the area of the bulbous urethra. It is also possible in this embodiment for the pressure source to act as an additional positioning means, which will aid in retaining the device within the urethra. The dilation balloon is of a length of at least that of the obstructed

-8-

portion of the urethra. Also shown in this figure is an attaching inserter member 40 which preferably can be detachable, leaving the stent in the urethra. However, optionally, it is to be understood that the inserter and stent can remain undetached, i.e., the device thereby functioning as a catheter. Means 42, illustratively in the form a
5 needle and septum, for attaching or detaching the catheter, can also be provided.

As stated above, draining lumen 28 extends through the device 22. Location balloon 38, dilation balloon 34 and pressure source 32 are also in fluid communication with each other through lumen 44 which extends through device 22. Port 39 permits the flow of fluid into location balloon 38. Ports 35 and 33 permit the flow of fluid into
10 the dilation balloon 34 and pressure source 32 respectively.

In operation, the passage of fluid from outside the penis through lumen 44 is controlled so that the positioning balloon 38 and the pressure source 32 are fully inflated, but in the context of this invention, the dilation balloon 34 is initially only partially inflated, i.e., to an extent less than that needed to impact with sufficient force
15 to dilate the obstructed portion of the urethra. In a preferred mode of operation, when pressure source 32 contracts due to the pressure differential between that of the pressure source and the pressure exerted on the dilation balloon by the hypertrophied prostate, fluid will flow at a predetermined rate from the pressure source into the dilation balloon so as to slowly and gradually expand the latter to the extent necessary for it to
20 impact with sufficient force to dilate the obstructed portion of the urethra. The rate of this flow can also be determined by the geometry and elastic modulus of the pressure balloon, which will contrast to the resistance of the prostate tissue surrounding the dilation balloon.

In Fig. 5 there is shown an embodiment of this invention in which the pressure
25 responsive balloon 32 also serves as a positioning balloon which would be adapted to be located in the bladder neck. Also shown in this figure is the single lumen 44 which is in fluid communication with the pressure responsive balloon 32 and serves to initially fully inflate the pressure responsive balloon.

However, in this embodiment, separate lumen 46 provides for the passage of
30 fluid from the contracting pressure balloon 32 into the dilation balloon 34, to effect the desired expansion of the latter. Lumen 46, as shown, continues to the end of the stent. Also shown is a fluid resistor 48 (which can be of a type well known in the art) which acts to control the rate of passage of fluid from pressure source 32 to dilation balloon

-9-

34 to enable the latter to expand gradually and slowly in accordance with the practice of this invention. The viscosity of the fluid further controls the rate of flow. Port 50 allows fluid to enter the dilation balloon from lumen 46. When deflation of the stent is required in order to remove the stent, a drainage plug 52 can be utilized. A suitable
5 plug is described in U.S. patent 5,112,306.

It is also to be understood that within the context of this invention that the pressure responsive means can optionally be disposed outside of the body in the form of, for example, a syringe pump or pump bulb. When such means are employed fluid can be transferred into the dilation means by applying suitable pressure in carefully
10 monitored amounts to thereby slowly dilate the dilation means.

As stated above, the diameter of the unexpanded devices of this invention should be on the order of between about 20 and about 26 French. Generally speaking, diameters of less than about 20 French will not permit adequate urination in combination with desired dilation, while the insertion into the meatus of the penis prior
15 to insertion into an obstructed prostatic urethra of an unexpanded device having a diameter of more than about 26 French will usually be too painful for a patient. It thus follows that the diameter of the lumens of the devices of this invention should be fixed within the tolerable limits of the diametral range of the unexpanded device, preferably on or about 20 French.

20 The gradual, slow dilation of the dilation balloon should occur over a period of at least 30 minutes, and preferably over a much longer period, a dilation which occurs at a rate of about 5 French per 20 hour period being particularly desirable. Thus if a dilated stent of 70 French is desired, and the initial stent diameter was about 20 French, the slow dilation could take as long as 9 or 10 days. A long expansion period may also
25 result in a longer patency for the resulting dilation. In this regard, the device of the subject invention is adapted to remain in the urethra for periods on the order of seven days to 30 days, the latter being a practical upper limit for retention in the urethra for biocompatible reasons, such as possible urinary tract infection, increased inflammation or bacterially based prostatitis.

30 For reasons which are not completely known, when the device of this invention is removed, the dilated urethra will tend to remain in its dilated configuration for a period on the order of about 12 to about 24 months, or longer, i.e., the patency of the urethral lumen or canal will tend to remain in its dilated state. It is believed that the

-10-

slow dilation causes pressure necrosis of the tissue with fibrous collagen deposition within the parenchyma of the prostate. The fibrous tissue is not physiologically active thus reducing the ability of the prostate to contract. This scarring of the gland is much like that which occurs in the myocardium after infarction.

- 5 It is apparent that other modifications and variations besides those specifically mentioned herein may be made in the devices described herein and depicted in the accompanying drawings without departing from the concept of the present invention.

CLAIMS

1. A device for slowly dilating an obstructed portion of a urethra which comprises:

5 a urinary catheter 22 for insertion into the urethra 10, said catheter having a proximal portion and a distal portion;

dilation means 34 capable of expanding radially outwardly, said means being disposed between said proximal and distal portion and having a length of at least that of the obstructed portion 12 of the urethra 10; and

10 pressure responsive means 32 which is capable of sequentially contracting under pressure;

said pressure responsive means 32 and dilation means 34 being in fluid communication through conduit means 44 or 46 which enables fluid to flow from said pressure responsive means 32, when the latter is contracting under pressure, into the dilation means 34 to cause the latter to gradually expand radially outwardly until dilation
15 of the obstructed portion 12 of the urethra 10 occurs to a desired diameter and configuration.

2. A device according to claim 1, wherein the dilation means 34 is capable of expanding radially outwardly at a predetermined rate.

3. A device according to claim 2, wherein the dilation means 34 is capable
20 of expanding at a rate of between about 5 French and about 20 French over a 24-hour period.

4. A device according to claim 3, wherein the pressure responsive means 32 is disposed at or near the distal portion of the catheter 22 and is capable of expanding with the onset of fluid.

25 5. A device according to claim 4, wherein, with the initial onset of fluid, the pressure responsive means 32 can be fully inflated, but the dilation means 34 is only partially inflated.

6. A device according to claim 3, wherein the dilation means 34 has an outer surface 36 capable of expanding radially outwardly for a period of at least about
30 30 minutes.

7. A device according to claim 6, wherein the dilation means 34 is in the form of an inflatable balloon 34.

-12-

8. A device according to claim 7, wherein the inflation balloon 34 is elastic without a defined limit of intrinsic expansion.

9. A device according to claim 7, wherein the balloon 34 has a defined shape and an intrinsic limit to expansion.

5 10. A device according to claim 4, wherein the pressure responsive means 32 is in the form of an expandable and contractible balloon 32 which can also act as a positioning balloon when located in the area of the bladder neck 18 of the body.

11. A device according to claim 4, wherein a separate positioning balloon 38 is adapted to be located in the bulbous urethra of the body.

10 12. A device according to claim 1, wherein fluid communication between the dilation means 34 and the pressure responsive means 32 is a single lumen 44 for effecting both inflation and deflation.

13. A device according to claim 1, wherein during the contracting mode of the pressure responsive means 32 fluid flows from said pressure responsive means 32 to said dilation means 34 by virtue of a conduit 46, which is disposed separate from the lumen 44 initially inflating the pressure responsive means.

14. A device according to claim 13, wherein a fluid resistor 48 is located between the dilation means 34 and pressure responsive means 32 along the path of the separately disposed lumen 46.

20 15. A device according to claim 4, wherein the catheter 22 is comprised of two elements, a stent containing the dilation means 34 and pressure responsive means 32 which can remain in the urethra 10 for a time sufficient that the obstructed portion 12 of the urethra 10 will tend to remain in a dilated configuration even after removal of the stent, and an attaching member 40 which is detachably removable.

25 16. A device according to claim 15, wherein the stent is adapted to remain in the urethra 10 for a period of between about 5 days and about 30 days, wherein the dilated urethra will then tend to remain in its dilated configuration for a period of between about 12 and about 24 months.

30 17. A device for slowly dilating an obstructed portion of a urethra which comprises:

a urinary catheter 22 for insertion into the prostatic urethra 12, said catheter 22 having a proximal portion and a distal portion;

-13-

a dilation balloon 34 capable of expanding radially outwardly, said balloon 34 being disposed between said proximal and distal portion and having a length of at least that of the obstructed portion 12 of the urethra 10; and

pressure responsive means 32 in the form of an expandable and contractible balloon 32 which is disposed at or near the distal portion of the catheter; said pressure responsive means 32 and dilation balloon 34 being in fluid communication through a lumen 44 or 46 which enables fluid to flow from said pressure responsive means 32, when the latter is contracting under pressure, into the dilation balloon 34 to cause the latter to gradually expand radially outwardly at a rate of between about 5 French and about 20 French over a 24 hour period until dilation of the obstructed portion 12 of the urethra 10 occurs to a desired diameter and configuration; and

wherein the lumen 46 includes a fluid resistor 48 along the path thereof.

18. A device according to claim 17, wherein the pressure responsive means 32 also acts as a positioning balloon when located in the area of the bladder neck 18 of the body.

19. A device according to claim 18, wherein the catheter 22 is comprised of two elements, a stent containing the dilation balloon 34 and pressure responsive means 32, which can remain in the obstructed portion 12 of the urethra 10 for a time sufficient that the dilated urethra will tend to remain in a dilated configuration even after removal of the stent, and an attaching member 40 which is detachably removable.

20. A method of dilating a portion of a urethra obstructed as a consequence of a hypertrophied prostate gland, which comprises the steps of:

inserting a device 22 into the urethra 10 having a length of at least that of the obstructed portion 12 of the urethra 10, said device comprising pressure responsive means 32 capable of expanding and contracting under predetermined conditions, and dilation means 34 which is in fluid communication with said pressure responsive means 32; and

sequentially transferring fluid from said pressure responsive means 32 into said dilation means 34 when the pressure responsive means 32 is under contraction, thereby causing the dilation means 34 to expand gradually for a period of at least about 30 minutes, thereby impacting upon the obstructed portion 12 of the

-14-

urethra 10 with sufficient force to cause said obstructed portion 12 to dilate to a desired diameter and configuration.


21. A method of treating benign prostatic hyperplasia, which comprises:
inserting a device 22 into a urethra 10 and 12 obstructed as a
5 consequence of the prostatic hyperplasia, said device comprising pressure responsive means 32 capable of expanding and contracting under predetermined conditions, and dilation means 34 which is in fluid communication with said pressure responsive means 32;

sequentially transferring fluid from said pressure responsive means 32
10 into said dilation means 34 when the pressure responsive means 32 is under contraction to cause the dilation means 34 to expand gradually for a period of at least about 30 minutes, thereby impacting upon the obstructed portion 12 of the urethra 10 with sufficient force to cause said obstructed portion 12 to dilate to a desired diameter and configuration;

15 leaving the device 22 in the urethra 10 and 12 for an extended period of time; and

then removing the device 22 from the urethra 10, the dilated portion 12 of the urethra 10 thereby tending to remain in such dilated configuration.

1/4



2/4

FIG. 2




FIG. 3






FIG. 4



4/4

FIG. 5



INTERNATIONAL SEARCH REPORT

Int. onal Application No
PCT/IB 96/00143

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61M25/10 A61M29/02 A61B17/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61M A61B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A,5 084 016 (FREEMAN ET AL.) 28 January 1992 see column 10, line 25 - column 11, line 27; figures 9,9A,9B	1,2,4-9, 12
Y	---	3,15-19
Y	US,A,5 167 627 (CLEGG ET AL.) 1 December 1992 see abstract	3,17-19
Y	---	15,16
	US,A,4 932 938 (GOLDBERG ET AL.) 12 June 1990 see column 13, line 30 - line 36; figure 22	

	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

26 April 1996

Date of mailing of the international search report

15. 05. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax (+31-70) 340-3016

Authorized officer

Ehrsam, F

INTERNATIONAL SEARCH REPORT

Int. onal Application No

PCT/IB 96/00143

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US,A,5 135 494 (ENGELSON ET AL.) 4 August 1992 see column 4, line 55 - column 5, line 54; figures 2,3 ---	15
A	EP,A,0 552 934 (MED INSTITUTE) 28 July 1993 see column 10, line 27 - column 12, line 12; figures 33,34,35A,39 ---	1,11,17
A	WO,A,86 05990 (WOLINSKY HARVEY) 23 October 1986 see figures 1-3 ---	1,11,17
A	US,A,4 546 756 (SOLARMLADEN) 15 October 1985 see column 3, line 1 - line 13; figure 2 -----	1,11,17

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB 96/00143

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 20, 21
because they relate to subject matter not required to be searched by this Authority, namely:
Method for treatment of the human body by therapy
See Rule 39.1(iv) PCT.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Appl. No.

PCT/IB 96/00143

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-5084016	28-01-92	US-A- 5024655	18-06-91
US-A-5167627	01-12-92	US-A- 5074846	24-12-91
		AU-B- 642038	07-10-93
		AU-B- 8387191	19-03-92
		CA-A- 2050816	14-03-92
		DE-D- 69115180	18-01-96
		EP-A- 0475324	18-03-92
		JP-A- 4226676	17-08-92
US-A-4932938	12-06-90	AU-B- 628541	17-09-92
		AU-B- 5470190	08-11-90
		CA-A- 2015831	05-11-90
		DE-A- 4014369	08-11-90
		FR-A- 2646610	09-11-90
		GB-A, B 2231801	28-11-90
		JP-A- 3109065	09-05-91
US-A-5135494	04-08-92	AU-B- 2307488	09-03-89
		CA-A- 1326423	25-01-94
		DE-D- 3884954	18-11-93
		DE-T- 3884954	03-02-94
		EP-A, B 0368931	23-05-90
		JP-T- 3502051	16-05-91
		JP-B- 4017667	26-03-92
		NO-B- 175138	30-05-94
		WO-A- 8901352	23-02-89
EP-A-552934	28-07-93	US-A- 5304214	19-04-94
		CA-A- 2087623	22-07-93
WO-A-8605990	23-10-86	DE-D- 3689681	07-04-94
		DE-T- 3689681	09-06-94
		EP-A- 0220236	06-05-87
		US-A- 4824436	25-04-89
US-A-4546756	15-10-85	NONE	